ArticleDigestion2026
Childhood-Onset Celiac Disease Autoimmunity and Risk of Depression and Anxiety across the Lifespan: A Longitudinal Analysis of a Large Real-World Cohort.
Article in Digestion, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCeliac disease is associated with various extraintestinal manifestations, including psychiatric and psychological comorbidities. We evaluated the risk of developing depression and anxiety among patients diagnosed with celiac disease autoimmunity (CDA).
methodsThis retrospective case-control cohort study was conducted using the Clalit Healthcare Services population-based electronic database (∼4.5 million individuals). Between January 1, 2008, and December 31, 2022, we identified subjects aged 1-80 years with a positive IgA anti-tissue transglutaminase test and a repeat measurement within 6-36 months. Depression and anxiety were identified over follow-up using ICD-9 diagnostic codes or by documented regular use of antidepressants or anxiolytics.
resultsWe identified 3,797 patients with CDA, and the cohort was matched in a 1:3 ratio with 11,387 healthy controls having a negative anti-tTG2 serology. Over a median 60-month follow-up duration, 5.9% of CDA patients developed depression or anxiety, compared to 1.7% of the control group (HR 2.89, 95% CI 2.2-3.8, p < 0.001), and 67% of anxiety and depression cases among CDA patients were developed during childhood. On multivariate analysis, very high baseline anti-tTG2 level (>10× ULN), older age at diagnosis, and female sex were independently associated with the risk of developing anxiety and depression among CDA patients (HR 1.82, 1.03, and 1.38; p values 0.029, 0.018, and 0.038, respectively).
conclusionsCDA appears to increase the risk for anxiety and depression, particularly with very high baseline anti-tTG2 levels, advanced age at diagnosis, and in females.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.